Silab has commissioned a second production line for unicellular organisms on site within its Biotechnologies Production Unit (UPB).
Fully independent, this production line integrates a 15,000 L principal bioreactor, giving the company the means to quadruple the annual production of these natural raw materials used to manufacture active ingredients.
Thanks to this industrial tool, which is automated and like other plants on the site, reportedly offers excellent ergonomics to technicians, the company plans to increase its share of natural active ingredients from microorganisms, which currently represents 20% of its catalog.
“They [the microorganisms] have potential due to their diversity and their metabolism,” said Brigitte Closs-Gonthier, Silab’s deputy general manager for innovation. “With this line, Silab now has the means to further diversify its production of microorganisms and master their properties, opening up access to some molecules of interest.”
“This €5 million capacity investment is part of a wider €30 million investment program, which has been implemented over three years,” added Xavier Gaillard, Silab’s deputy general manager for strategy. “This program stems from our desire to offer the cosmetic and dermo-cosmetic market solutions while responding to the current major challenges of security, traceability and sustainability of sourcing.”
For more information, contact Silab.